Payers have taken a cautious approach to handling rising demand for the pricey new class of drugs known as glucagon-like peptide agnostics, or GLP-1s.
from Section Page News - Modern Healthcare https://ift.tt/1AXs5eW
Health tips in Tamil and English & more unique news updates too, " Health is wealth " so, Read data and be strong and healthy!!
Payers have taken a cautious approach to handling rising demand for the pricey new class of drugs known as glucagon-like peptide agnostics, or GLP-1s.
Insurers could lose young, healthy customers and providers could suffer greater uncompensated care costs if exchange enrollment drops.
Insurers and employers are taking a renewed interest in programs that help people deal with chronic — and potentially expensive — health problems.
The insurance group hopes to defend a Trump-era policy allowing employers to subsidize individual market coverage for their workers.